




Searching News Database: Daiichi Sankyo
HSMN NewsFeed - 12 Aug 2019
Daiichi Sankyo, Inc. Appoints Simon King as Chief People Officer across U.S. Divisions
Daiichi Sankyo, Inc. Appoints Simon King as Chief People Officer across U.S. Divisions
HSMN NewsFeed - 22 Feb 2019
Daiichi Sankyo Shifts Several Top Leaders to New Roles for Company's Launch into its Next Growth Phase
Daiichi Sankyo Shifts Several Top Leaders to New Roles for Company's Launch into its Next Growth Phase
HSMN NewsFeed - 30 Jul 2018
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
HSMN NewsFeed - 11 Jun 2018
IO Biotech Appoints Kathleen Sereda Glaub as Member of Board of Directors
IO Biotech Appoints Kathleen Sereda Glaub as Member of Board of Directors
HSMN NewsFeed - 8 May 2018
TFF Pharmaceuticals Announces Appointment of Glenn Mattes as New Chief Executive Officer
TFF Pharmaceuticals Announces Appointment of Glenn Mattes as New Chief Executive Officer
HSMN NewsFeed - 27 Apr 2017
Rigel Announces Tavalisse(TM) as Proprietary Name for Fostamatinib in the United States
Rigel Announces Tavalisse(TM) as Proprietary Name for Fostamatinib in the United States
HSMN NewsFeed - 17 Apr 2017
Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP
Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP
HSMN NewsFeed - 14 Jul 2016
Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan
Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan
HSMN NewsFeed - 18 Jan 2016
Michael Martino Named President and Chief Executive Officer of HemaFlo Therapeutics
Michael Martino Named President and Chief Executive Officer of HemaFlo Therapeutics
HSMN NewsFeed - 16 Oct 2015
Daiichi Sankyo, Inc. Reorganizes its U.S. Commercial Operations to Support Upcoming Specialty Pipeline
Daiichi Sankyo, Inc. Reorganizes its U.S. Commercial Operations to Support Upcoming Specialty Pipeline
HSMN NewsFeed - 19 Mar 2015
Daiichi Sankyo Signs Agreement With AstraZeneca To Co-Commercialize MOVANTIK In The US
Daiichi Sankyo Signs Agreement With AstraZeneca To Co-Commercialize MOVANTIK In The US
HSMN NewsFeed - 10 Sep 2014
Afferent Pharmaceuticals Names Kathleen Sereda Glaub as Chief Executive Officer
Afferent Pharmaceuticals Names Kathleen Sereda Glaub as Chief Executive Officer
HSMN NewsFeed - 16 May 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
HSMN NewsFeed - 17 Aug 2011
Daiichi Sankyo, Inc. Appoints Executive Vice President of Drug Development for the Americas
Daiichi Sankyo, Inc. Appoints Executive Vice President of Drug Development for the Americas
HSMN NewsFeed - 17 Jun 2011
Seattle Genetics Announces Promotion of Eric Dobmeier to Chief Operating Officer
Seattle Genetics Announces Promotion of Eric Dobmeier to Chief Operating Officer
HSMN NewsFeed - 20 May 2011
Amgen Receives CHMP Positive Opinion for XGEVA (Denosumab) in the European Union
Amgen Receives CHMP Positive Opinion for XGEVA (Denosumab) in the European Union
HSMN NewsFeed - 26 Jul 2010
FDA Approves Tribenzor, A New Three-In-One Combination Product for the Treatment of High Blood Pressure
FDA Approves Tribenzor, A New Three-In-One Combination Product for the Treatment of High Blood Pressure
HSMN NewsFeed - 24 May 2010
Seattle Genetics Names Vice President, Sales and Announces Management Promotion
Seattle Genetics Names Vice President, Sales and Announces Management Promotion
HSMN NewsFeed - 15 Mar 2010
Ranbaxy Announces Settlement of Actos(R) (Pioglitazone Hydrochloride) Patent Litigation
Ranbaxy Announces Settlement of Actos(R) (Pioglitazone Hydrochloride) Patent Litigation
HSMN NewsFeed - 11 Feb 2010
Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs
Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs
HSMN NewsFeed - 11 Feb 2010
FDA Approves Benicar(R) for the Treatment of High Blood Pressure in Children and Adolescents aged 6-16
FDA Approves Benicar(R) for the Treatment of High Blood Pressure in Children and Adolescents aged 6-16
HSMN NewsFeed - 4 Jan 2010
Boston Scientific Announces Enrollment of First Patient in Post-Approval Study for TAXUS Liberte Stent
Boston Scientific Announces Enrollment of First Patient in Post-Approval Study for TAXUS Liberte Stent
HSMN NewsFeed - 13 Oct 2009
Seattle Genetics Names Head of Commercial and Announces Management Promotion
Seattle Genetics Names Head of Commercial and Announces Management Promotion
HSMN NewsFeed - 21 May 2009
Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial
Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial
HSMN NewsFeed - 13 May 2009
AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure
AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure
HSMN NewsFeed - 30 Mar 2009
Seattle Genetics Receives FDA Fast Track Designation for SGN-35 for the Treatment of Hodgkin Lymphoma
Seattle Genetics Receives FDA Fast Track Designation for SGN-35 for the Treatment of Hodgkin Lymphoma
HSMN NewsFeed - 23 Feb 2009
European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI
European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI
HSMN NewsFeed - 3 Feb 2009
Prasugrel Receives Unanimous Approval Recommendation from FDA Advisory Committee
Prasugrel Receives Unanimous Approval Recommendation from FDA Advisory Committee
HSMN NewsFeed - 31 Dec 2008
FDA Cardio Renal Advisory Committee to Review Daiichi Sankyo, Lilly Drug Prasugrel
FDA Cardio Renal Advisory Committee to Review Daiichi Sankyo, Lilly Drug Prasugrel
HSMN NewsFeed - 3 Nov 2008
DAIICHI SANKYO Acquires Merck Serono's Cardio-Metabolism Sales Force and Products in Turkey
DAIICHI SANKYO Acquires Merck Serono's Cardio-Metabolism Sales Force and Products in Turkey
HSMN NewsFeed - 16 Sep 2008
Fresenius Medical Care Announces Closing of the U.S. License Agreement for Intravenous Iron Products
Fresenius Medical Care Announces Closing of the U.S. License Agreement for Intravenous Iron Products
HSMN NewsFeed - 12 Sep 2008
CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group
CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group
HSMN NewsFeed - 17 Jul 2008
Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation
Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation
HSMN NewsFeed - 21 May 2008
Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG
Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG
HSMN NewsFeed - 27 Feb 2008
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
HSMN NewsFeed - 21 Jan 2008
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults With Type 2 Diabetes
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults With Type 2 Diabetes
HSMN NewsFeed - 19 Jan 2008
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
HSMN NewsFeed - 18 Dec 2007
Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
HSMN NewsFeed - 2 Dec 2007
FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
HSMN NewsFeed - 5 Sep 2007
Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
HSMN NewsFeed - 21 Aug 2007
Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR(TM)
Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR(TM)
HSMN NewsFeed - 11 Jul 2007
StemCyte Appoints Robert Dickey IV as Senior Vice President and Chief Financial Officer
StemCyte Appoints Robert Dickey IV as Senior Vice President and Chief Financial Officer
HSMN NewsFeed - 4 Jun 2007
YM BioSciences Cleared to Initiate Clinical trial of Nimotuzumab in Colorectal Cancer
YM BioSciences Cleared to Initiate Clinical trial of Nimotuzumab in Colorectal Cancer
HSMN NewsFeed - 1 May 2007
Response Submitted to FDA Approvable Letter for Hypertension Compound Nebivolol
Response Submitted to FDA Approvable Letter for Hypertension Compound Nebivolol
HSMN NewsFeed - 16 Apr 2007
YM BioSciences' partner Daiichi Sankyo receives clearance for initial clinical trial in Japan
YM BioSciences' partner Daiichi Sankyo receives clearance for initial clinical trial in Japan
HSMN NewsFeed - 28 Mar 2007
Daiichi Sankyo, Inc. Announces Filing For WelChol Label Change to Include Ezetimibe Efficacy Data
Daiichi Sankyo, Inc. Announces Filing For WelChol Label Change to Include Ezetimibe Efficacy Data
HSMN NewsFeed - 14 Dec 2006
Cerexa to Be Acquired by Forest Laboratories for $480 Million Plus Potential $100 Million Milestone Payment
Cerexa to Be Acquired by Forest Laboratories for $480 Million Plus Potential $100 Million Milestone Payment
HSMN NewsFeed - 13 Nov 2006
WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
Additional items found! 2

Members Archive contains
2 additional stories matching:
Daiichi Sankyo
(Password required)
Daiichi Sankyo
(Password required)